Graft Versus Leukaemia and Immunotherapy Group

The Graft-versus-Leukaemia (GVL) and Immunotherapy Group investigates the mechanisms of inherent immunogenicity of haematological malignancies and immune responses against leukaemia.

This includes studies of natural killer cells, T cell responses against tumour-associated antigens and immune suppressor cells in patients with Chronic Myeloid Leukemia (CML) and in patients who have received stem cell transplantation.

The group’s research program aims to determine more effective immune-targeted therapy in leukaemia and to develop more accurate prognostic tests to enable more CML patients to achieve treatment-free remission, which will be translated into clinical practice. The research group is also furthering cellular and immunotherapy for leukaemia treatment by the development of chimeric antigen receptor (CAR) T cell therapy for myeloid leukaemia.